An Allergen BioCube (ABC) Study Evaluating the Onset of Action of Fluticasone Furoate Nasal Spray and Olopatadine Nasal Spray Compared to Placebo

Inclusion Criteria: * provide written informed consent and signed HIPAA form; * be able and willing to follow all instructions and attend the study visits; * if female and of childbearing potential, be not pregnant, nursing or planning a pregnancy, be willing to submit a pregnancy test at visit 1 and at exit visit, and to use adequate method of birth control * have a positive history of seasonal allergic rhinitis to ragweed; * have a positive skin test reaction to ragweed of within the past 24 months; * manifest sufficient allergic rhinitis symptoms during ragweed exposure in the ABC Exclusion Criteria: * manifest symptoms of clinically active allergic rhinitis at the start of Visit 1 or Visit 2; * known intolerance or allergy to antihistamines or corticosteroids; * have a compromised lung function at Visit 1; * have significant nasal anatomical deformities or any condition that does not allow subject to breathe through the nose (includes, but is not limited to: septal deviation, septal perforations, nasal polyps, rhinitis medicamentosa) * have had any nasal surgical intervention in the past; * have planned surgery (nasal, ocular or systemic) during the trial period or within 30 days thereafter; * use disallowed medications (topical, topical ophthalmic, systemic and/or injectable treatments and all anti-allergy therapies including prescription, over the counter or homeopathy, and over the counter sleeping aids) during the study or appropriate pre-study washout period